DERM vs. ARCT, SIGA, CDXC, KROS, ABVX, ZVRA, GLUE, ANAB, ATXS, and UPB
Should you be buying Journey Medical stock or one of its competitors? The main competitors of Journey Medical include Arcturus Therapeutics (ARCT), SIGA Technologies (SIGA), ChromaDex (CDXC), Keros Therapeutics (KROS), ABIVAX Société Anonyme (ABVX), Zevra Therapeutics (ZVRA), Monte Rosa Therapeutics (GLUE), AnaptysBio (ANAB), Astria Therapeutics (ATXS), and Upstream Bio (UPB). These companies are all part of the "pharmaceutical products" industry.
Journey Medical vs.
Arcturus Therapeutics (NASDAQ:ARCT) and Journey Medical (NASDAQ:DERM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, community ranking, earnings, valuation and risk.
Journey Medical has a net margin of -31.74% compared to Arcturus Therapeutics' net margin of -36.39%. Arcturus Therapeutics' return on equity of -22.39% beat Journey Medical's return on equity.
In the previous week, Arcturus Therapeutics and Arcturus Therapeutics both had 2 articles in the media. Journey Medical's average media sentiment score of 0.97 beat Arcturus Therapeutics' score of 0.73 indicating that Journey Medical is being referred to more favorably in the news media.
Journey Medical has lower revenue, but higher earnings than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Journey Medical, indicating that it is currently the more affordable of the two stocks.
Arcturus Therapeutics currently has a consensus target price of $65.00, indicating a potential upside of 265.79%. Journey Medical has a consensus target price of $9.67, indicating a potential upside of 86.26%. Given Arcturus Therapeutics' higher possible upside, equities analysts plainly believe Arcturus Therapeutics is more favorable than Journey Medical.
Arcturus Therapeutics has a beta of 2.62, indicating that its share price is 162% more volatile than the S&P 500. Comparatively, Journey Medical has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500.
Arcturus Therapeutics received 437 more outperform votes than Journey Medical when rated by MarketBeat users. However, 100.00% of users gave Journey Medical an outperform vote while only 66.17% of users gave Arcturus Therapeutics an outperform vote.
94.5% of Arcturus Therapeutics shares are held by institutional investors. Comparatively, 7.3% of Journey Medical shares are held by institutional investors. 15.3% of Arcturus Therapeutics shares are held by insiders. Comparatively, 13.2% of Journey Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Arcturus Therapeutics beats Journey Medical on 10 of the 17 factors compared between the two stocks.
Get Journey Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for DERM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Journey Medical Competitors List
Related Companies and Tools
This page (NASDAQ:DERM) was last updated on 2/23/2025 by MarketBeat.com Staff
